Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model

C. Joaquín Cáceres1, Stivalis Cardenas-García1, Silvia Carnaccini2, Brittany Seibert1, Daniela S. Rajao1, Jun Wang3* & Daniel R. Perez1*

The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the defining global health emergency of this century. GC-376 is a Mpro inhibitor with antiviral activity against SARS-CoV-2 in vitro. Using the K18-hACE2 mouse model, the in vivo antiviral efficacy of GC-376 against SARS-CoV-2 was evaluated. GC-376 treatment was not toxic in K18-hACE2 mice. Overall outcome of clinical symptoms and survival upon SARS-CoV-2 challenge were not improved in mice treated with GC-376 compared to controls. The treatment with GC-376 slightly improved survival from 0 to 20% in mice challenged with a high virus dose at 10⁵ TCID50/mouse. Most notably, GC-376 treatment led to milder tissue lesions, reduced viral loads, fewer presence of viral antigen, and reduced inflammation in comparison to vehicle-treated controls in mice challenged with a low virus dose at 10³ TCID50/mouse. This was particularly the case in the brain where a 5-log reduction in viral titers was observed in GC-376 treated mice compared to vehicle controls. This study supports the notion that GC-376 represents a promising lead candidate for further development to treat SARS-CoV-2 infection and that the K18-hACE2 mouse model is suitable to study antiviral therapies against SARS-CoV-2.

The coronavirus disease (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the defining global health crisis of our time. As of March 3, 2020, more than 110 million cases of COVID-19 have been reported, associated with 2.54 million deaths. SARS-CoV-2 belongs to the Coronaviridae family, which are RNA viruses commonly associated with mild upper respiratory illness. In the past few years, novel coronaviruses have emerged from animal reservoirs crossing the species barrier causing sporadic outbreaks in humans such as SARS-CoV and the Middle Eastern Respiratory Syndrome (MERS). The current global health emergency prompted a race to develop resources to combat the pandemic. Several vaccines against SARS-CoV-2 are currently in different stages of pre-clinical or clinical evaluation. Among these, several have received emergency use approval in several countries, most notably the Pfizer/BioNTech's and Moderna's mRNA-based vaccines, the first of their kind approved for human use. Additionally, a number of viral proteins and host factors have been proposed as small molecule antiviral drug targets to combat SARS-CoV-2 infection. Among those, the viral main protease (Mpro) is one of the most extensively explored drug targets, and a number of Mpro inhibitors are in different stages of preclinical and clinical development. GC-376 is a representative Mpro inhibitor that has shown antiviral activity against Feline Infectious Peritonitis (FIP) CoV in experimentally infected cats. The ~30 kb viral genome SARS-CoV-2 genome encodes two polyproteins, pp1a and pp1ab, which must be cleaved in order to be functional and lead to active viral replication. Cleavage is mediated by the Mpro and the papain-like (PLpro) proteases, both are potential antiviral targets. In vitro studies have shown inhibition of SARS-CoV Mpro in the presence of GC376. More recently, the potential antiviral activity of GC-376 against SARS-CoV-2 has been demonstrated in vitro, placing GC-376 as a promising antiviral candidate for treatment of SARS-CoV-2 infections. However, the antiviral activity of GC-376 against SARS-CoV-2 in vivo has not been addressed, neither have any other Mpro inhibitors that are currently in development. Therefore, to fulfill the knowledge gap and provide insights of the translational potential of Mpro inhibitors as SARS-CoV-2 antivirals, we report in this...
study the in vivo antiviral efficacy of GC-376 in mice. We used the transgenic K18-hACE2 mice model, which expresses the human angiotensin-converting enzyme type 2 (hACE2) receptor, under the control of the keratin 18 promoter. At the time of writing of this report, several groups showed that K18-hACE2 mice develop clinical signs and mortality after SARS-CoV-2 challenge. SARS-CoV-2 challenge doses of 1 × 10^3 TCID50/mouse were used that produced clinical signs of disease and mortality that correlated with the virus dose administered. Modest differences in terms of clinical signs, weight loss, and survival were observed between GC-376 and vehicle mice. Further analyses indicated that GC-376/SARS-CoV-2 challenged mice showed lower viral loads, milder tissue lesions and reduced inflammation compared to vehicle SARS-CoV-2 challenged controls indicating that GC-376 can act as a SARS-CoV-2 antiviral in vivo.

**Materials and methods**

**Ethics statement.** Studies were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Georgia (Protocol A2019 03-032-Y2-A9). Studies were conducted under animal biosafety level 3 containment. Animal studies and procedures were performed according to the Institutional Animal Care and Use Committee Guidebook of the Office of Laboratory Animal Welfare and PHS policy on Humane Care and of Use of Laboratory Animals. Animal studies study were carried out in compliance with the ARRIVE guidelines (https://arriveguidelines.org). Animals were humanely euthanized following guidelines approved by the American Veterinary Medical Association (AVMA).

**Cells and virus.** Vero E6 Pasteur were kindly provided by Maria Pinto (Center for Virus research, University of Glasgow, Scotland, UK). Cells were maintained in Dulbecco's Modified Eagles Medium (DMEM, Sigma-Aldrich, St Louis, MO) containing 10% fetal bovine serum (FBS, Sigma-Aldrich, St Louis, MO), 1% antibiotic/antimycotic (AB, Sigma-Aldrich, St Louis, MO) and 1% L-Glutamine (Sigma-Aldrich, St Louis, MO). Cells were cultured at 37 °C under 5% CO2. SARS-CoV-2 (Isolate USA-WA1/2020) was kindly provided by Dr. S. Mark Tompkins, Department of Infectious Diseases, University of Georgia. Viral stocks were prepared in Vero E6 Pasteur cells. Briefly, cells in a T75 flask was incubated 1 h with 1 ml of viral inoculum. After incubation, the inoculum was removed and cells were cultured with DMEM containing 2% FBS, 1% AB. After 96 h, the supernatant was collected, centrifuged at 15,000 g for 15 min., aliquoted and stored at −80 °C until use. Viral stocks were titrated by tissue culture infectious dose 50 (TCID50) and virus titers were established by the Reed and Muench method [18].

**Chemical compounds.** GC-376 (CAS: 1416992-39-6) was purchased from Enovation chemicals (Green book, NY) and dissolved in deionized water (HyClone, VWR, West Chester, PA) to the desired concentration.

**Mouse studies.** 6-week-old female K18-hACE2 mice were purchased from Jackson laboratories (Bar Harbor, ME). Mice were randomly distributed in the number of groups (Fig. 1A), anesthetized with isoflurane and intranasally infected (i.n.) with 50 µl of either phosphate buffer saline (PBS), or 1 × 10^3 TCID50/mouse or bor, ME). Mice were randomly distributed in the number of groups (Fig. 1A), anesthetized with isoflurane and intranasally infected (i.n.) with 50 µl of either phosphate buffer saline (PBS), or 1 × 10^3 TCID50/mouse. At 3 h post-challenge, GC-376 (20 mg/kg/dose, 40 mg/kg daily) or vehicle (H2O) was administered to each mouse through intraperitoneal injection (i.p.) and continued for 7 days, twice per day. Mice were monitored twice daily for clinical signs of disease along the entire course of the experiment. Mice that lost ≥25% of their initial body weight (a score of 3 on a 3-point scale of disease severity) were humanely euthanized. At 2 and 5 dpc, subsets mice (n = 2/time point from G1 and G2 and n = 3/time point from G3, G4, G5, and G6) received an overdose of isoflurane, and were humanely euthanized. Lungs, nasal turbinates (NT), spleen, liver, small intestine (SI) and brain were collected from each mouse post-mortem. Tissues were stored at −80 °C until further analysis. At 14 dpc, the same procedure was performed with the remaining animals.

**Tissue sample preparations.** Tissue homogenates were generated using the Tissue Lyzer II (Qiagen, Gaithersburg, MD). Briefly, 500 µl of PBS-AB was added to each sample along with Tungsten carbide 3 mm beads (Qiagen). Samples were homogenized during 10 min and then centrifuged at 15,000 g for 10 min. Supernatants were collected, aliquoted and stored at −80 °C until further analysis.

**RNA extraction and RT-qPCR.** RNAs were extracted from the different tissue homogenates using the MagMAX-96 AI/ND viral RNA isolation kit (ThermoFisher Scientific, Waltham, MA) following manufacturer’s protocol. A one-step real time quantitative PCR (RT-qPCR) based on the Nucleoprotein gene segment was used as surrogate of viral load and it was employed using the primers 2019-nCov_N2-F (5′-TTAACACATTGGCCGCAA-3′) and 2019-nCov_N2-R (5′-GGCCGACATTCCGAAGAA-3′). A probe with FAM as a reporter and TAMRA as a quencher was used (5′-FAM-ACAATTGGCCGGAAGCTTAC-G-TAMRA-3′). The RT-qPCR was performed in a QuantStudio 3 Real-Time PCR System (ThermoFisher Scientific, Waltham, MA) using a Quantabio qScript XLT One-Step RT-qPCR ToughMix kit (Quantabio, Beverly, MA) in a final reaction volume of 20 µl. Each reaction mixture contained 1 × master mix, 0.5 µM forward and reverse primers, 0.3 µM probe, and 5 µl of RNA. The qPCR cycling conditions were 50 °C, 20 min; 95 °C, 1 min, 40 cycles at 95 °C, 1 min; 60 °C, 1 min; and 72 °C 1 s; with a final cooling step at 4 °C. A standard curve was generated using tenfold serial dilutions of a SARS-CoV-2 virus stock of known titer to correlate RT-qPCR crossing point (Cp) values with the viral load from each tissue. Viral loads were calculated as Log10 TCID50 equivalents per gram of tissue.

**Histopathology and immunohistochemistry.** Selected tissues, including lungs, NT, spleen, liver, heart, SI, and brain were collected from a representative number of mice in each group and at different timepoints (2,
and 14 dpc) for histopathological examination. Tissues were placed in 10% neutral-buffered formalin (NBF), fixed for at least 72 h, paraffin embedded and processed for routine histopathology with hematoxylin and eosin staining (HE). Tissues were subjectively scored by a pathologist as none (0), mild; ≤ 10% (1), mild to moderate; 11–25% (2), moderate; 26–40% (3), moderate to severe; 41–60% (4) and severe; ≥ 60% (5) based on % of the total parenchyma affected by lesions and inflammation. Features considered for the scoring were the following: presence and extent of necrosis, hemorrhage, edema (interstitial and/or alveolar), fibrin/hyaline membranes, thrombi, pneumocyte type 2 hypertrophy and hyperplasia, syncytia, mesothelial hyperplasia, pneumonia, bronchitis/bronchiolitis, pleuritis and vasculitis. Additionally, antibodies targeting the SARS-CoV-2 nucleoprotein (N) (ThermoFisher Scientific, Waltham, MA; dilution 1/500), the CD3 receptor (Agilent technologies, Santa Clara, CA; dilution 1/1000) and the allograft inflammatory factor 1 (Iba1) (Fujifilm WAKO chemicals, Richmond, VA; dilution 1/8000) were also used to perform immunohistochemistry (IHC) on selected tissues. The staining was used to estimate the amount of viral nucleocapsid (N), CD3 and Iba1 antigens. Staining intensity and distribution were subjectively scored by a pathologist blinded to the study using a scale from none (0) to large/highest positivity (5).

Figure 1. Schematic representation of the experimental design and evaluation of the safety of GC-376 in K18shACE2 mice. (A) K18-hACE2 were either mock challenged (G1 and G2) or challenged with SARS-CoV-2 at either a high virus dose (1 × 10^5 TCID50/mouse; G3 and G4) or a low virus dose (1 × 10^3 TCID50/mouse; G5 and G6). I.P. treatment with vehicle (G1, G3, and G5) or GC-376 (G2, G4, and G6, 40 mg/kg/day). Subsets of mice were humanely euthanized at 2 and 5 dpc and different tissues were collected. Mice (n = 8) received 40 mg/kg of GC-376 split in two doses per day for 7 days and (B) weight changes and (C) survival were monitored for 12 days. (D) Mice were humanely euthanized at 14 dpc and lungs, brain, liver, spleen, heart and SI were collected. HE slides were generated and analyzed in comparison with the negative control group. Representative pictures were taken at 20× magnification for all tissues except brain samples that were taken at 4×. SARS-CoV-2 illustration was obtained from the CDC image library (free of any copyright restrictions image ID#23312 by Eckert and Higgins, https://phil.cdc.gov/Details.aspx?pid=23312). Mouse clipart was obtained from the Clipart Library, with permission.
Results

GC-376 is not toxic in K18-hACE2 mice. GC-376 is effective against FIP CoV in cats and against SARS-CoV-2 in vitro. We evaluated the efficacy of GC-376 against SARS-CoV-2 in vivo using the K18-hACE2 mouse model (Fig. 1A). Concomitantly, we evaluated the potential toxicity of GC-376 in K18-hACE2 mice, noting that previous studies have shown no liver toxicity caused by GC-376 in other mouse strains at the dose administered in this study. K18-hACE2 mice were either mock-challenged (PBS, G1, n = 6/group and G2, n = 8/group), challenged with a high dose of SARS-CoV-2 virus (1 × 10⁵ TCID50/mouse, G3 and G4, n = 11/group), or challenged with a low dose of SARS-CoV-2 virus (1 × 10² TCID50/mouse, G5 and G6, n = 11/group). At 3 h post-challenge, mice were treated for 7 days, twice daily i.p. with either vehicle (G1, G3, and G5) or GC-376 (G2, G4, and G6, 40 mg/kg daily, 20 mg/kg each dose). No significant weight loss and 100% survival was observed in both the mock-challenged mice treated with GC-376 (G2) and the mock-challenged vehicle control group (G1, Fig. 1B,C). Furthermore, lungs, brain, liver, small intestine, spleen and heart did not present any tissue alteration at 14 days post-treatment with GC-376 in comparison with the vehicle control group (Fig. 1D).

Effect of GC-376 treatment on the clinical outcome in mice challenged with SARS-CoV-2. In mice challenged with the high virus dose (G3 and G4), there was a period of relatively normal activity (response to the environment and stimulus given by the personnel) and physical appearance (Fig. 2A,B) followed by rapid weight loss and presentation of clinical signs (Fig. 2C). By 6 dpc, mice in G3 (high virus dose/vehicle, white symbols) showed about 20% weight loss and by 8 dpc there were no survivors because they have either succumbed to the infection or had to be humanely euthanized due to severe clinical signs (lethargy, ruffled fur, labored breathing, and/or ≥ 25% body weight loss, Fig. 2D). These observations are consistent with previous reports. G4 mice (high virus dose/GC-376) showed similar clinical signs but such progression was delayed by about 24 h (~ 15% weight loss by 6 dpc). In terms of body weight loss, statistically significant differences were established between G3 and G4 in comparison to G1 from 4 to 6 dpc. Of note, the G4 mice (high virus dose/GC-376) showed 20% survival (n = 1 out of 5) but such difference was not statistically significant. We analyzed whether the antiviral activity of GC-376 could improve disease outcome when a low challenge dose of SARS-CoV-2 was used. As expected, progression of the disease occurred slower compared to groups of mice challenged with the high virus dose (G3 and G4, Fig. 2A–D). It was interesting to observe transient reduced activity and deterioration of physical appearance (Fig. 2E,F) regardless of treatment accompanied by consistent and statistically significant body weight loss between 5 to 7 dpc in all mice regardless of group at the low virus challenge dose compared to mock-challenged/vehicle treated mice, ultimately leading to 60% survival (Fig. 2G,H). These observations are significant because it suggests that disease progression due to SARS-CoV-2 infection in the k18-hACE2 mouse model is virus dose dependent adding more value to the system to better study SARS-CoV-2 pathogenesis and host responses. Of note, a trend towards increased weight loss but faster body weight recovery was observed in G6 mice (low virus dose/GC-376) compared to G5 mice (low virus dose/vehicle). However, and despite the 100 times lower virus challenge dose, we did not notice an improvement in the clinical outcome of mice treated with GC-376 compared to mice in vehicle control group. Taken together, these results suggest that GC-376 has modest benefit in K18-hACE2 mice infected with SARS-CoV-2 in terms of clinical signs outcome, weight changes, and survival.

Graphs/statistical analyses. All data analyses and graphs were performed using GraphPad Prism software version 8 (GraphPad Software Inc., San Diego, CA). For multiple comparisons, two-way analysis of variance (ANOVA) was performed. A P value below 0.05 was considered significant.

A trend towards reduced SARS-CoV-2 vRNA loads in GC-376-treated mice. To better characterize the effect of GC-376 treatment against SARS-CoV-2, sections of NT, lungs, brain, liver, small intestine (SI) and spleen were collected at 2 and 5 dpc and each tissue split into two to assess vRNA viral loads and for histopathological analyses, respectively. Tissue homogenates were prepared, vRNA extracted and then vRNA loads and vRNA tissue distribution were evaluated by RT-qPCR. High vRNA content consistent with active virus replication was observed in tissue homogenates from the NT, lungs, and brain of mice in G3 (high virus dose/vehicle). RT-qPCR results were consistent with the clinical observations in G3 mice, with average higher vRNA signals at 2 dpc than at 5 dpc in samples from the lungs and NT, but the opposite in other tissues (brain, liver, SI and spleen) indicative of systemic virus spread (Fig. 3A). Likewise, vRNA loads in G5 mice (low virus dose/vehicle) followed disease progression with higher average signals on 5 dpc compared to 2 dpc, particularly in the brain where these differences were statistically significant (Fig. 3A). Also consistent with the clinical outcome of the disease, reduced vRNA load averages were observed in NT, lungs and brain samples from mice in G4 (high virus dose/GC-376) compared to homologous samples from mice in G3 (high virus dose/vehicle). Samples from mice in G4 showed more individual variations in vRNA loads, several at levels below limit of detection, than the counterparts in G3 (Fig. 3B). Similarly, more individual variations in vRNA levels were observed in NT, lungs and brain samples from G6 mice (low virus dose/GC-376) than in G5 mice (low virus dose/vehicle) (Fig. 3C). Interestingly, brain samples from G6 mice showed statistically significant lower vRNA levels than those from G5 mice. Overall, these results suggest high levels of SARS-CoV-2 replication in the NT, lungs, and brain of K18-hACE2 mice and detectable vRNA in liver, SI and spleen. GC-376 treatment leads towards reduced virus load averages with the caveat of noticeable individual variations among treated animals, and the inability to properly prevent the burden and mortality caused by SARS-CoV-2 in K18-hACE2 mice. At the low dose virus challenge, GC-376 prevented to great extent the virus’ ability to reach the brain, but such effect was not correlated with increased survival compared to vehicle-treated controls.
Figure 2. Efficacy of GC-376 in terms of clinical signs and survival after challenge with SARS-CoV-2. Mice (n = 11/group) were challenged with a (A–D) high dose (1 × 10^5 TCID50/mouse) or (E–H) low dose (1 × 10^3 TCID50/mouse) of SARS-CoV-2 and treated with drug vehicle (white symbols) or 40 mg/kg of GC-376 split in two doses per day for 7 days (black symbols). (A, E) activity, (B, F) physical appearance, (C, G) weight change and (D, H) survival (n = 5). Statistical analysis was performed by a two-way ANOVA, *p < 0.05. Grey shading represents remaining number of animals at time of clinical evaluation (n = 11; dark grey, n = 8; mid grey, n = 5 light grey).
Effects of GC-376 on SARS-CoV-2-induced pathology in mice. Histopathological analysis of lungs, NT, and brains at 2, 5, and 14 dpc (Table 1) showed overall milder lesions in mice treated with GC-376 and challenged with the low dose virus (Fig. 4). At 2 dpc, no differences were observed in the two groups challenged with the high dose (G3 and G4). Lesions at 2 dpc consisted of mild-moderate interstitial lymphoplasmacytic and histiocytic inflammation especially centered around vessels and peribronchiolar spaces (Fig. 4A,B, asterisks). In addition, marked edema was effacing the alveoli and interstitium in the G3 group (red arrowheads). At 2 dpc, G5 and G6 (low dose/vehicle and low dose/GC-376) presented similar but milder extent of lymphoplasmacytic and histiocytic inflammation (Fig. 4C,D, asterisks) compared to high dose groups. At 5 dpc, interstitial pneumonia in both G4 and G3 (high dose/GC-376 and high dose/vehicle) groups increased in severity and percentage of parenchyma affected (Fig. 4F,G) and again no significant differences in scoring were observed. Alveolar septal...
thickening and consolidation were caused by the severe proliferation of type II pneumocytes and lymphoplasma- 

cytic inflammation (Fig. 4F, G arrowhead and asterisk, respectively). In addition, the high dose/vehicle G3 

group presented a more pronounced neutrophilic inflammation (Fig. 4G white arrowhead) with necrosis of 

alveolar septa, hemorrhage and presence of binucleated, and multinucleated epithelial cells (syncytia) sloughing 

into the alveolar lumen. Mild-moderate pleuritis was often observed in the affected groups. Despite the minimal differences observed at 5 dpc in the high dose challenged groups, 2 out of 3 mice treated with GC-376 and 

challenged with the low dose, did not present any pulmonary lesions (Fig. 4H). In the low dose/vehicle group, 

mice presented mild to moderate lesions similar to what was already described in the previous high dose groups 

(G3 and G4). These also included marked alveolar edema and pleuritis (Fig. 4I, red arrowhead and black arrow, 

respectively). Airways were mostly spared of lesions, presenting occasional blebbing and sloughing of bronchial 

epithelial cells into the lumen (Fig. 4F, G, I). By 14 dpc, none to minimal lesions were observed in G4 (high dose/ 

GC-376, only one survivor) (Fig. 4K), whereas in G3 (high dose/vehicle) lesions at 14 dpc could not be evaluated 

because there were no survivors. At 14 dpc, the mice in G6 (low dose/GC-376) presented mild-moderate mul-

tifocal perivascular cuffing forming lymphoid nodular aggregates (Fig. 4L, asterisk). The G5 low dose/vehicle 

mice presented sparser lymphoplasmacytic and histiocytic infiltrates similar to the one observed at day 2 dpc 

(Fig. 4M, asterisk).

Lesions in the olfactory epithelium of the NT were minimal, only observed in 2 out of 3 mice at 2 dpc, in G4 

(high dose/GC-376), G3 and G5 (high virus dose/vehicle and low virus dose/vehicle, respectively). These also included marked alveolar edema and pleuritis (Fig. 4I, red arrowhead and black arrow, 

respectively). Airways were mostly spared of lesions, presenting occasional blebbing and sloughing of bronchial 

epithelial cells into the lumen (Fig. 4F, G, I). By 14 dpc, none to minimal lesions were observed in G4 (high dose/ 

GC-376, only one survivor) (Fig. 4K), whereas in G3 (high dose/vehicle) lesions at 14 dpc could not be evaluated 

because there were no survivors. At 14 dpc, the mice in G6 (low dose/GC-376) presented mild-moderate mul-
tifocal perivascular cuffing forming lymphoid nodular aggregates (Fig. 4L, asterisk). The G5 low dose/vehicle 

mice presented sparser lymphoplasmacytic and histiocytic infiltrates similar to the one observed at day 2 dpc 

(Fig. 4M, asterisk).

Lesions in the olfactory epithelium of the NT were minimal, only observed in 2 out of 3 mice at 2 dpc, in G4 

(high dose/GC-376), G3 and G5 (high virus dose/vehicle and low virus dose/vehicle, respectively) at all time-

points, and none in G6 (low dose/GC367). These consisted of vacuolar degeneration, pyknosis and karyorrhexis 

of random single mucosal epithelial cells (Fig. 4O arrowheads).

In G3 (high dose/vehicle) NT lesions were accompanied by infiltration of mild numbers of neutrophils, 

macrophages, and lymphocytes (Fig. 4P, arrowhead). No lesions were observed in any of the mice from G6 (low 

dose/GC-376) (Fig. 4Q) similar to G1 (Fig. 4S). In contrast, G5 (low dose/vehicle) presented lesions similar to 

G3 (high dose/vehicle), with mild degeneration of the olfactory epithelial cells and mild mixed inflammatory 

infiltrate (Fig. 4R, arrow and arrowheads). At 5 dpc, the brain of mice in G4 and G3 (high dose/GC-376 and 

high dose/vehicle), presented similarly from none to mild microscopic lesions that consisted mostly of mild 

gliosis, lymphoplasmacytic and histiocytic meningoencephalitis (Fig. 4T–U arrowheads). Interestingly, none of 

the mice in the G6 (low dose/GC-376) group presented brain lesions (Fig. 4V), as opposed to mice in G5 (low 

dose/vehicle) which presented lesions similar to the high dose challenge groups (Fig. 4W).

Reduced inflammatory cell distribution and SARS-CoV-2 virus staining in GC-376 treated mice 

challenged with a low virus dose. Viral antigen in lungs was readily detected in lungs of G3 and G4 

(high dose/vehicle and high dose/GC376 respectively) with little variations in the distribution, prevalence in the 

section and intensity of the staining (Fig. 5A, B). In the case of G6 and G5 (low dose/GC-376 and low dose/vehi-

ce), viral antigen was present, but lower in G6 compared to G5 (Fig. 5C, D). By 5 dpc, amount of viral antigen 

increased with no appreciable difference between high dose or low dose challenge groups (Fig. 5F–I). In lungs, 

viral antigen staining was observed within the cytoplasm of pneumocytes type I, II, and alveolar macrophages.
In NT, viral antigen at 2 dpc was observed in 1 out of 3 mice in G4 (high dose/GC376) and in 2 out of 3 mice in G3 high dose/vehicle (Fig. 5K,L). In mice challenged with the low virus dose, viral antigen was not detected in G6 mice (low dose/GC-376) whereas 3 out of 3 mice showed mild positive staining in G5 (low dose/vehicle) at 2 dpc (Fig. 5M,N). Viral antigen in NT was located in the cytoplasm of the ciliated epithelial cells of the respiratory mucosa and in the olfactory cells of the pseudostratified olfactory epithelium.

Despite the mild histopathological lesions, the brain presented extensive viral antigen positivity in neurons of G4 and G3 (high dose/GC376 and high dose/vehicle, respectively) at 5 dpc with no relevant differences (Fig. S5PQ, arrowheads). Viral antigen was distributed in neurons of both the white and grey matters, and randomly across the olfactory bulb, cerebrum, limbic system (e.g., hippocampus, hypothalamus, thalamus) and brainstem. Interestingly, when challenged with the low dose, no antigen was detected in any of the mice in G6 (low virus dose/GC-376) in contrast with all the mice in G5 (low virus dose/vehicle) which presented moderate to large amounts of viral antigen in the brain at 5 dpc (Fig. S5RS). This suggested a lower SARS-CoV-2 replication preventing the spreading of the virus in the presence of GC-376. These observations are consistent with the vRNA load data by RT-qPCR for both of these groups (Fig. 3C). As expected, tissue samples from G1 (mock challenge/vehicle) showed absence of viral antigen staining (Fig. S5EJOT).
IHC using antibodies against CD3 or Iba1 was performed to better characterize the type and extent of the cellular inflammatory infiltrate, T lymphocytes and cells of the monocyte/macrophage lineage, respectively (Table 2). No significant differences in numbers of CD3+ cells in any organ were noticed between vehicle-treated mice or GC-376 treated mice challenged with the high dose SARS-CoV-2 at the given timepoints (Fig. 6, panels 1–2, 6–7, 11–12, 16–17). On the contrary, a clearly lower number of CD3+ cells were observed at both 2 and 5 dpc in the lungs, NT and brain of G6 mice (low virus dose/GC-376) compared to G5 mice (low virus dose/vehicle) (Fig. 6, panels 3–4, 8–9, 13–14, 18–19). This suggests a potential implication of GC-376 in preventing more severe inflammation and virus-induced tissue damage (Fig. 6; Table 2). Similar results were observed with Iba1 IHC, showing similar staining patterns in the organs from the high dose challenge groups but lower staining overall in G6 (low dose/GC-376) when compared against its control G5 (low dose/vehicle) (Fig. 6, panels 21–40). Findings were overall consistent with the extent of inflammatory reaction and lesions observed by HE.

Figure 5. SARS-CoV-2 virus nucleocapsid tissue distribution in lungs, NT and brain analysis through IHC. (A,F) G4, lungs, 2 and 5 dpc, respectively; moderate amount of virus antigen (red staining) is present within pneumocyte type I, II, and alveolar macrophages. (B,G) G3, lungs, 2 and 5 dpc, respectively; moderate amount of virus N antigen (red staining) is present within pneumocyte type I, II. (C,H) G6, lungs, 2 and 5 dpc, respectively; rare pneumocytes type I and II present intracytoplasmic viral nucleocapsid at 2 dpc and normal lungs at 5 dpc. (D,I) G5, lungs, 2 and 5 dpc, respectively; mild numbers of cells (pneumocyte type I, II, and alveolar macrophages) present virus antigen positivity within the cytoplasm (arrowheads). (E,J) G1, normal lungs at 2 and 5 dpc, respectively. (K,L) G4 and G3, respectively, NT, 2 dpc; mild amount of intracytoplasmic virus antigen within olfactory epithelium. (M) G6, normal NT, 2 dpc. (N) G5, NT, 2 dpc; moderate amount of virus nucleocapsid present within both respiratory epithelium and olfactory epithelium. (O) G1, normal NT, 2 dpc (P,Q) G4 and G3, respectively, brain, 5 dpc; moderate to large amount of virus antigen within neurons (arrowheads). (R) G6, normal brain, 5 dpc. (S) G5, brain 5 dpc; moderate to large amount of virus antigen within neurons (arrowheads). (T) G1, normal brain, 5 dpc. Pictures were taken at 20 × magnification and inserts were taken at 40 × magnification.
### Table 2. CD3 and Iba1 IHC scores of different treatment groups. A dash (–) is used to separate the score of each individual mouse evaluated in each case.

| Group                  | DPC | Lungs   | Brain    | Nasal Turbinates |
|------------------------|-----|---------|----------|------------------|
|                        |     | CD3     | Iba1     | CD3              | Iba1   | CD3   | Iba1   |
| G1 mock-Ch/vehicle     | 2   | 0–0     | 0–0      | 0–0              | 0–0    | 0–0   | 0–0   |
|                        | 5   | 0–0     | 0–0      | 0–0              | 0–0    | 0–0   | 0–0   |
| G2 mock-Ch/GC-376      | 2   | 0–0     | 0–0      | 0–0              | 0–0    | 0–0   | 0–0   |
|                        | 5   | 0–0     | 0–0      | 0–0              | 0–0    | 0–0   | 0–0   |
| G3 High dose/vehicle   | 2   | 3–2–2   | 2–1–1    | 0–0              | 0–0    | 0–0–0 | 0–0   |
|                        | 5   | 2–3–3   | 3–4–4    | 1–0–3            | 3–0–3  | 1–1   | 1–1   |
| G4 High dose/GC-376    | 2   | 1–2–1   | 1–1–1    | 0–0              | 0–0    | 0–0–2 | 1–1–1 |
|                        | 5   | 2–4–3   | 2–4–4    | 2–0–0            | 3–1–0  | 1–1–1 | 1–0–0 |
| G5 Low dose/vehicle    | 2   | 0–1–1   | 0–0–2    | 0–0              | 0–0    | 0–0–1 | 1–1–1 |
|                        | 5   | 1–3–2   | 1–4–1    | 1–1–2            | 0–2–0  | 1–1–1 | 1–2–1 |
| G6 Low dose/GC-376     | 2   | 2–0–0   | 1–0–1    | 0–0              | 0–0    | 0–0–0 | 1–0–0 |
|                        | 5   | 0–4–0   | 0–3–0    | 0–0              | 0–0    | 0–1–0 | 1–1–0 |

---

**Figure 6.** T-cell and monocyte/macrophages accumulation in lung, NT and brain from GC-376- and vehicle-treated mice at selected timepoints. (1–4, 6–7, 9) Increased numbers of T lymphocytes are expanding perivascular and peribronchiolar spaces (arrowheads) and invading the interstitium (asterisks) at 2 and 5 dpc in G4, G3, G6 and G5. In G6, 2/3 mice did not present any increase in T-cells at 5 dpc. (5, 10) G1, normal lungs from uninfected control mice at 2 and 5 dpc, respectively. Note resident CD3+ lymphocyte concentrations in the resting tissue. (11–12, 14) Mild increase in T-cells were observed in G4, G3 and G5 NT at 2 dpc invading lamina propria and olfactory epithelium (arrowheads). (13, 15) No increase in CD3+ staining was observed in G6 and G1 NT at 2 dpc. (16–17, 19) Mild-moderate increase in perivascular T-cells was observed in G4, G3, and G5 brains at 5 dpc. (18, 20) No increase in CD3+ staining was observed in G6 and G1 brains at 5 dpc. (21–24, 26–27, 29) Increased numbers of Iba1+ cells were found effacing perivascular and peribronchiolar spaces (arrowheads) and invading the interstitium (asterisks) at 2 and 5 dpc in G4, G3, G6 and G5. (28) G6, 2/3 mice did not present any increase in T-cells at 5 dpc. (25, 30) G1, normal lungs from uninfected control mice at 2 and 5 dpc, respectively. Note resident Iba1+ macrophages concentrations in the resting tissue. (31–32, 34) Mild increase in macrophages were observed in G4, G3 and G5 NT at 2 dpc invading lamina propria and olfactory epithelium (arrowheads and inserts). (33, 35) No increase in Iba1+ staining was observed in G6 and G1 NT at 2 dpc. (36–37, 39) Mild-moderate increase in perivascular macrophages was observed in G4, G3, and G5 brains at 5 dpc accompanied by marked increased in staining of resident microglial cells within areas of intense virus antigen positivity (arrowheads). (38, 40) No increase in Iba1+ staining was observed in G6 and G1 brains at 5 dpc. Pictures and inserts were taken at 20× and 40× magnification, respectively.
Taken together, these results suggest that GC-376 is able to prevent to some extent the inflammatory reactions induced by SARS-CoV-2 infection.

Discussion

In the last two decades, coronaviruses have been implicated in significant zoonotic outbreaks (SARS-CoV-1 in 2003 and MERS in 2012) and in the COVID-19 pandemic (SARS-CoV-2 in 2019/2020). The current COVID-19 pandemic has caused more than 45 million confirmed infections associated to more than 1 million deaths worldwide, a public health emergency of incomparable proportions in the twenty-first century. Many anti-SARS-CoV-2 antiviral efforts have focused on the repurposing of antivirals compounds rather than the development of novel compounds. Among those, drugs such as hydroxychloroquine (HCQ), remdesivir, favipiravir, ivermectin, among others have been proposed as promising candidates. There are currently more than 50 different clinical trials where compounds with potential antiviral activity are under evaluation. Previous studies have shown HCQ antiviral activity in vitro against SARS-CoV-1 and, early during the COVID-19 pandemic, against SARS-CoV-223,24. However, further analysis in animal models (hamsters and monkeys) and in human clinical trials showed that HCQ is ineffective against SARS-CoV-2 in vivo25–27. More promising outcomes have been observed with remdesivir, an adenosine nucleoside triphosphate analog, that shows antiviral activity in vitro and in mice against a surrogate chimeric SARS-CoV-2 virus28–30. More importantly, remdesivir was shown to shorten the time to recovery of COVID-19 hospitalized patients31,32. The FDA has recently approved the remdesivir for treatment of COVID-19 patients, ages ≥12 years old and weighing ≥40 lb, that require hospitalization. However, remdesivir may offer limited benefits to those that are severely ill. More importantly, a press release from the WHO on November 20, 2020 recommends against the use of remdesivir in COVID-19 patients. Immunotherapy using convalescent plasma or monoclonal antibodies is another avenue of great focus in the treatment of COVID-19. In this regard, the FDA has recently released an emergency use authorization for the investigational monoclonal antibody therapy Bamlanivimab (LY-CoV555, Eli Lilly) to treat mild-to-moderate COVID-19 in adult and pediatric patients with high risk to become severely ill or hospitalized (typically those ≥65 years of age or who have certain chronic medical conditions). It is important to mention that neither bamlanivimab nor REGN-COV2 (Regeneron) immunotherapies have proven effective in COVID-19 patients requiring mechanical ventilation (33,34 and NCT04426695). Thus, there is still a long road ahead in the development of adequate countermeasures against the SARS-CoV-2 virus.

Herein we evaluated the antiviral activity in vivo of GC-376, a compound that has shown antiviral activity against SARS-CoV-2 in vitro. For these studies we used the K18-hACE2 mouse model which was previously established as a suitable small animal model of SARS-CoV-1 infection. We must note that at the time we initiated our studies, no reports were available in the public domain regarding the suitability of the K18-hACE2 mouse model to study SARS-CoV-2 infection. Since then, several reports have emerged and our results are in agreement with the notion that the K18-hACE2 mouse model is a suitable small animal model to study SARS-CoV-2 pathogenesis. Previous reports have also shown that K18-hACE2 mice are amenable for the study of vaccines against SARS-CoV-2 but, to our knowledge, assessment of this mouse model for the evaluation of potential antivirals against SARS-CoV-2 was lacking. We observed clinical signs of disease and mortality in K18-hACE2 mice upon SARS-CoV-2 challenge in a virus dose-dependent manner (Figs. 3 and 4). Severe clinical signs and 0% survival was observed at the high virus challenge dose in contrast to the relatively delayed onset of clinical signs and 60% survival at the low virus challenge dose demonstrating that this model is not hypersusceptible to the SARS-CoV-2 virus. Data on clinical signs and body weight monitoring indicated that mice in the low virus challenge dose were indeed infected and those that survived were essentially devoid of clinical signs by 14 dpc. This is relevant since the K18hACE2/SARS-CoV-2 model offers the opportunity to study disease outcome and host responses which in humans are thought to be related, at least in part, to the amount of virus during exposure. In contrast, other mouse models, either transduced with a recombinant adenovirus or modified with CRISPR/Cas9 to express hACE2, have shown limited susceptibility to SARS-CoV-2 and/or neither apparent clinical signs nor mortality.

The toxicity of GC-376 (7-day course at 40 mg/kg/day) was evaluated through changes in body weight and survival (Fig. 2) and histopathological changes in different tissues at 7 days post-treatment (14 dpc). These analyses indicated lack of obvious acute toxicity of GC-376 in K18-hACE2 mice. Although previous studies in cats showed no GC-376 associated toxicity, those were performed using lower doses than in our studies. Additionally, no specific toxicity evaluations were performed in studies using GC-376 against murine hepatitis virus (MHV) A59 in Balb/c mice.

We observed a modest although clearly beneficial effect of GC-376 against SARS-CoV-2 in vivo based on the collective analysis of the following observations: slight delay in onset of clinical signs accompanied by one survivor in the GC-376-treated group compared to no survivors in the vehicle-treated mice challenged with a high virus dose. More interindividual variations with several more tissue samples showing vRNA levels below levels of detection comparing GC-376-treated to vehicle-treated animals challenged with either high or low virus dose. Although not statistically significant, average lower vRNA levels were observed in tissue samples from the NT, lungs, and brain in mice treated GC-376 than in the vehicle-treated counterparts. Faster body weight recovery and significantly reduced vRNA presence in brain samples collected at 5 dpc was observed in GC-376-treated versus vehicle-treated mice challenged with low dose virus. The reduced vRNA load in brain samples was consistent with reduced viral antigen staining. Reduced virus involvement in the brain is important considering the neurologic features observed in COVID-19 patients where disorientation, poorly organized movements and confusion among other neurological symptoms have been observed. Additionally, COVID-19 neurological symptoms can be potentially life threatening in around 65% of the cases. A positive effect of GC-376 was also supported by the histopathological examinations and analysis of markers of cellular infiltration (CD3 and Iba1).
Milder lesions and lower detection of CD3+ and Iba1+ cells in lungs, NT and brain samples were observed in GC-376-treated mice compared to vehicle-treated mice. The decrease in CD3+ and Iba1+ cells was correlated with milder inflammation also observed at HE. A lower, measured inflammatory response is thought to be favorable for the host, in contrast with an excessive inflammatory reaction, such as the multisystemic inflammatory syndrome, which is considered a major complication of SARS-CoV-2 infection, often fatal in COVID-19 patients.

The widespread virus colonization of neurons and associated meningoencephalitis observed in mice, partially explains the neurological deficits observed COVID-19 patients. Various infective mechanisms and paths can be exploited by the virus to reach the central nervous system. SARS-CoV-2 can access the brain through various neural or hematogenous routes that connect nasal mucosa, primary site of virus replication, to the anatomically adjacent forebrain across the cribriform plate of the ethmoid bone. Various reports suggest that virus dissemination to the brain is likely to occur from the upper respiratory tract via non-neuronal cells that provide metabolic and structural support to sensory olfactory nerve cells.

The modest in vivo antiviral activity of GC-376 in SARS-CoV-2-infected K18hACE2 mice is consistent with its moderate in vitro antiviral activity. The reported in vitro EC$_{50}$ values of GC-376 against SARS-CoV-2 in cell culture range from 0.5 to 3.4 µM from several independent studies, depending on the cell type and assay conditions. In comparison, a GC-376 analog 6j was recently reported to improve survival in MERS-CoV-infected mice, and the EC$_{50}$ value of the in vitro cellular antiviral activity of 6j against MERS-CoV was 0.04 ± 0.02 µM. This result suggests that the in vitro cellular antiviral activity of GC-376 against SARS-CoV-2 needs to be improved by 10–100-fold to achieve desired in vivo antiviral efficacy. As such, the lead optimization on GC-376 should mainly focus on improving the cellular antiviral activity. Alternatively, higher doses of GC-376, alone or in combination with other antivirals such as remdesivir or EIDD-2801 and/or anti-inflammatory drugs such as dexamethasone could be evaluated against SARS-CoV-2. Although such studies are beyond the scope of the present report, they are undoubtedly warranted. This is particularly the case since currently approved intervention strategies are limited and not very efficacious to treat severe COVID-19 cases. To our knowledge, ours is the first to study the in vivo efficacy of GC-376 against SARS-CoV-2. The precedent successful examples of GC-376 in treating FIP CoV infection and 6j in treating MERS-CoV infection in mice, coupled with the promising anti-inflammatory effects of GC-376 against SARS-CoV-2 infection in mice from this current study, warrants further development of GC-376 to specifically target SARS-CoV-2.

Received: 16 December 2020; Accepted: 15 April 2021
Published online: 05 May 2021

References

1. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (Accessed 2 September 2020) (2020).
2. Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744–753 e744. https://doi.org/10.1016/j.cell.2020.06.011 (2020).
3. Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2024671 (2020).
4. Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601. https://doi.org/10.1038/s41467-020-16505-0 (2020).
5. Al hindy, B. A., Lee, M. W. C., Ng, Y. L., Mok, C. K. & Chu, J. J. H. Current perspective of antiviral strategies against COVID-19. ACS Infect. Dis. 6, 1624–1634. https://doi.org/10.1021/acsinfecdis.0c0036 (2020).
6. Pedersen, N. C. et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J. Feline Med. Surg. 20, 378–392. https://doi.org/10.1111/jfms.12796 (2018).
7. Kim, Y. et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. 12, e1005531. https://doi.org/10.1371/journal.ppat.1005531 (2016).
8. Li, Q. & Kang, C. Progress in developing inhibitors of SARS-CoV-2 3C-like protease. Microorganisms 8, 1250. https://doi.org/10.3390/microorganisms8081250 (2020).
9. Kim, Y. et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 86, 11754–11762. https://doi.org/10.1128/JVI.01348-12 (2012).
10. Rathnayake, A. D. et al. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci. Transl. Med. 12, eabc5332. https://doi.org/10.1126/scitranslmed.abc5332 (2020).
11. Vuong, W. et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 11, 4282. https://doi.org/10.1038/s41467-020-18996-2 (2020).
12. Ma, C. et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30, 678–692. https://doi.org/10.1038/s41422-020-0356-z (2020).
13. Fu, L. et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 11, 4417. https://doi.org/10.1038/s41467-020-18233-x (2020).
14. McCray, P. B. J. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813–821. https://doi.org/10.1128/JVI.00122-06 (2007).
15. Rathnasighe, R. et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. bioRxiv https://doi.org/10.1101/2020.07.06.200966 (2020).
16. Yinda, C. K. et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. bioRxiv https://doi.org/10.1101/2020.08.11.246314 (2020).
17. Golden, J. W. et al. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight https://doi.org/10.1172/jci.insight.142032 (2020).
18. Reed, I. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).
19. Kim, Y. et al. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. J. Virol. 89, 4942–4950. https://doi.org/10.1128/JVI.03688-14 (2015).
20. Seo, S. H. & Jang, Y. Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection. Vaccines (Basel) https://doi.org/10.3390/vaccines8040584 (2020).
21. Oladunni, F. S. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 11, 6122. https://doi.org/10.1038/s41467-020-19991-7 (2020).
22. NIH. https://clinicaltrials.gov (Accessed 10 October 2020) (2020).
23. Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* **6**, 16. https://doi.org/10.1038/s41421-020-01356-0 (2020).

24. Weston, S. et al. Broad anti-coronavirus activity of Food and Drug Administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. *J. Virol.* https://doi.org/10.1128/JVI.01218-20 (2020).

25. Kaptein, S. J. F. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. *Proc. Natl. Acad. Sci. U.S.A.* https://doi.org/10.1073/pnas.201441117 (2020).

26. Maisonnasse, P. et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. *Nature* **585**, 584–587. https://doi.org/10.1038/s41586-020-2558-4 (2020).

27. Boulay, D. R. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. *N. Engl. J. Med.* **383**, S17–S25. https://doi.org/10.1056/NEJMoa2016638 (2020).

28. Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* **30**, 269–271. https://doi.org/10.1038/s41422-020-0282-0 (2020).

29. Prijssiers, A. J. et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. *Cell Rep.* **32**, 107940. https://doi.org/10.1016/j.celrep.2020.107940 (2020).

30. Hashemian, S. M., Farhadi, T. & Velayati, A. A. A review on remdesivir: A possible promising agent for the treatment of COVID-19. *Drug Des. Devel. Ther.* **14**, 3215–3222. https://doi.org/10.2147/DDDT.S261154 (2020).

31. Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—Final report. *N. Engl. J. Med.* https://doi.org/10.1056/NEJMoa2007764 (2020).

32. Pan, H. et al. Repurposed antiviral drugs for COVID-19—Interim WHO SOLIDARITY trial results. *MedRxiv* (2020).

33. Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. *Science* https://doi.org/10.1126/science.abc2402 (2020).

34. Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. *N. Engl. J. Med.* https://doi.org/10.1056/NEJMoa2029849 (2020).

35. Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. *Cell Host Microbe* **28**, 124-133 e124. https://doi.org/10.1016/j.chom.2020.05.020 (2020).

36. Helms, J. et al. Neurologic features in severe SARS-CoV-2 infection. *N. Engl. J. Med.* **382**, 2268–2270. https://doi.org/10.1056/NEJMmc2008597 (2020).

37. Bertram, B. et al. Research Square. https://doi.org/10.21023/rs.3-rs-43687/v1 (2020).

38. Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. *Nat. Rev. Immunol.* **20**, 355–362. https://doi.org/10.1038/s41577-020-0331-4 (2020).

39. Barrantes, F. J. Central nervous system targets and routes for SARS-CoV-2: Current views and new hypotheses. *ACS Chem. Neurosci.* **11**, 2793–2803. https://doi.org/10.1021/acschemneuro.0c00434 (2020).

40. Braun, D. H. et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. *Sci. Adv.* **6**, eabc5801. https://doi.org/10.1126/sciadv.abc5801 (2020).

41. Sacco, M. D. et al. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M(pro) and cathepsin L. *Sci. Adv.* https://doi.org/10.1126/sciadv.abe0751 (2020).

**Acknowledgements**

We thank the personnel from the Animal Health Research Center and the Histology laboratory, College of Veterinary Medicine, University of Georgia. This study was supported by a subcontract from the Center for Research on Influenza Pathogenesis (CRIP) to D.R.P under contract HHSN27220140008BC from the National Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS). J.W. thanks the support from the National Institutes of Health (NIH) (Grants AI147325 and AI157046) and the Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS) to D.R.P under contract HHSN27220140008C from the National Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS).

**Author contributions**

C.J.C., J.W. and D.R.P designed the experiments. C.J.C., S.C.G. and B.S. performed the experiments, samples collection and samples processing. S.C. performed IHC, histopathology examination and edited the manuscript. J.W. provided the GC-376 used in this study. C.J.C. and D.R.P analyzed the data and wrote the manuscript. All authors approved the final version of the manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to J.W. or D.R.P.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021